XOMA Royalty Corp files DEFA14A

This supplemental filing from Ligand Pharmaceuticals Incorporated announces its proposed acquisition of XOMA Royalty Corporation for "$39 a share in cash" plus a Contingent Value Right (CVR) tied to litigation proceeds from XOMA's dispute with Janssen Biotech over Tremfya. Ligand expects the transaction to close in the third quarter of 2026 and be "immediately accretive to earnings," adding "approximately $0.50 to Ligand’s adjusted earnings in 2026" and "$1.50 in 2027."